Dermatologic features of ADA2 deficiency in cutaneous polyarteritis nodosa

JAMA Dermatology

Volumn 151, Issue 11, 2015, Pages 1230-1234

  Santiago, Tania M Gonzalez ^a   Zavialov, Andrey ^b   Saarela, Janna ^c   Seppanen, Mikko ^c   Reed, Ann M ^d   Abraham, Roshini S ^a   Gibson, Lawrence E ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF TURKU   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

^d Mayo Clinic College of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DEAMINASE 2 DEFICIENCY; ADULT; ARTICLE; CASE REPORT; CECR1 GENE; CHILD; CLINICAL FEATURE; CUTANEOUS POLYARTERITIS NODOSA; DISEASE ASSOCIATION; ENZYME DEFICIENCY; ETHNICITY; EXOME; FEMALE; GENE; GENE MUTATION; GENE SEQUENCE; GENETIC VARIABILITY; HETEROZYGOTE; HUMAN; HUMAN TISSUE; MALE; PHENOTYPE; POLYARTERITIS NODOSA; PRIORITY JOURNAL; SCHOOL CHILD; SEX DIFFERENCE; SIBLING; SKIN BIOPSY; YOUNG ADULT; ADOLESCENT; GENETICS; MUTATION; PATHOLOGY; SKIN DISEASE;

ADENOSINE DEAMINASE; CECR1 PROTEIN, HUMAN; SIGNAL PEPTIDE;

ADENOSINE DEAMINASE; ADOLESCENT; CHILD; FEMALE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MUTATION; POLYARTERITIS NODOSA; SIBLINGS; SKIN DISEASES;

EID: 84946865962     PISSN: 21686068     EISSN: 21686084     Source Type: Journal    
DOI: 10.1001/jamadermatol.2015.1635     Document Type: Article

References (13)

1. Cohen RD, Conn DL, Ilstrup DM. Clinical features, prognosis, and response to treatment in polyarteritis. Mayo Clin Proc. 1980;55(3):146-155.
2. Lindberg K. Ein Beitrag zur Kenntnis der Periarteritis nodosa. Acta Med Scand. 1931;76:183-225.
3. Ozen S, Ruperto N, DillonMJ, et al. EULAR/PReS endorsed consensus criteria for the classification of childhood vasculitides. Ann Rheum Dis. 2006;65 (7):936-941.
4. Navon Elkan P, Pierce SB, Segel R, et al. Mutant adenosine deaminase 2 in a polyarteritis nodosa vasculopathy. N Engl J Med. 2014;370(10):921-931.
5. Zhou Q, Yang D, Ombrello AK, et al. Early-onset stroke and vasculopathy associated with mutations in ADA2. N Engl J Med. 2014;370(10):911-920.
6. Zavialov AV, Engstrom A. Human ADA2 belongs to a new family of growth factors with adenosine deaminase activity. Biochem J. 2005;391(pt 1):51-57.
7. Belot A,Wassmer E, Twilt M, et al. Mutations in CECR1 associated with a neutrophil signature in peripheral blood. Pediatr Rheumatol Online J. 2014; 12:44.
8. McColl SR, St-OngeM, Dussault AA, et al. Immunomodulatory impact of the A2A adenosine receptor on the profile of chemokines produced by neutrophils. FASEB J. 2006;20(1):187-189.
9. Garg N, Kasapcopur O, Foster J II, et al. Novel adenosine deaminase 2 mutations in a child with a fatal vasculopathy. Eur J Pediatr. 2014;173(6):827-830.
10. Giannelou A, Zhou Q, Kastner DL. When less is more: primary immunodeficiency with an autoinflammatory kick. Curr Opin Allergy Clin Immunol. 2014;14(6):491-500.
11. Van Eyck L Jr, Hershfield MS, Pombal D, et al. Hematopoietic stem cell transplantation rescues the immunologic phenotype and prevents vasculopathy in patients with adenosine deaminase 2 deficiency. J Allergy Clin Immunol. 2015;135(1): 283-287.e5.
12. Adair TH. Growth regulation of the vascular system: an emerging role for adenosine. Am J Physiol Regul Integr Comp Physiol. 2005;289(2): R283-R296.
13. Caorsi R, Omenetti A, Picco P, et al. Long-term efficacy of etanercept in ADA2 deficiency. Pediatr Rheumatol Online J. 2014;12(suppl 1):72.